Key facts
- Aisthesis Medical’s last known valuation is $5.2M (Sep 2025).
- It has raised $1.3M; the latest was Accelerator/Incubator in Mar 2026.
- Notable investors include Microsoft for Startups, AWS Startups, Twin Path Ventures, Caelestinus, Barclays Eagle Lab — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Aisthesis Medical
- ·The full record, as it builds
Funding rounds
No funding rounds for Aisthesis Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aisthesis Medical
Developer of an artificial intelligence-powered clinical decision-support system designed to predict and prevent critical health risks such as sepsis in acute care environments. The company's platform integrates data from wearable devices, bedside monitors, and electronic health records to build digital patient twins, enabling clinicians to receive explainable, guideline-informed insights that support timely and effective interventions.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2022
- Employees
- 8
- Website
- aisthesismed.com/
- Ownership
- Privately Held (backing)
Aisthesis Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aisthesis Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aisthesis Medical in its N-PORT filings yet. We sweep new filings monthly.